News for Altimmune, Inc. (ALT1.MX)

GAITHERSBURG, Md., March 03, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. ( ALT), a late clinical-stage biopharmaceutical company, today announced that members of

**media[555335]**

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

Feb 27, 2025 / 01:30PM GMTOperator Good day, ladies and gentlemen, and welcome to Altimmune fourth quarter and full year 2024 financial results conference call.

Altimmune, Inc. (NASDAQ:ALT) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ETCompany ParticipantsLee Roth - President, Burns McClellan,...

**media[552088]**

Top-line data from Phase 2b IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) to be reported in Q2 2025 Investigational Ne

Ms. Lawver, former Chief Commercial Officer of Dexcom and Global Vice President at Johnson & Johnson responsible for billion-dollar Immunology and Cardiovascula

**media[545501]**

On December 31, 2024, AMERIPRISE FINANCIAL INC (Trades, Portfolio) executed a noteworthy transaction by acquiring 1,378,854 shares of Altimmune Inc (ALT) at a t

Move over, Novo Nordisk and Eli Lilly. Why Pfizer and Roche look like top choices for investors.

Move over, Novo Nordisk and Eli Lilly. Why Pfizer and Roche look like top choices for investors.

Jim Cramer, the host of Mad Money, recently shared some investment guidelines based on his 40 years of experience.

Jim Cramer, the host of Mad Money, recently shared some investment guidelines based on his 40 years of experience.

Altimmune joins Nasdaq Biotechnology Index

GAITHERSBURG, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. ( ALT), a clinical-stage biopharmaceutical company, today announced that members of the C

**media[476556]**

We recently compiled a list of the 11 Reddit Stocks with Biggest Upside Potential. In this article, we are going to take a look at where Altimmune Inc.

Pemvidutide shows promise in metabolic disease trial